ECE2019 Poster Presentations Interdisciplinary Endocrinology 2 (37 abstracts)
Differences in gut microbiota between patients with gestational diabetes treated with insulin in comparison to those treated with metformin: preliminary analysis
María Molina-Vega 1 , María José Picón-César 1 , Carolina Gutiérrez-Repiso 2 , Isabel Moreno-Indias 2 , Stella González Romero 3 , Fuensanta Lima-Rubio 2 & Francisco Tinahones-Madueño 1
1Hospital Universitario Virgen de la Victoria, Malaga, Spain; 2Instituto de Investigación Biomédica de Málaga (IBIMA), Malaga, Spain; 3Hospital Universitario Regional de Málaga, Malaga, Spain.
Objective: To evaluate changes in gut microbiota induced by treatment in patients with gestational diabetes mellitus (GDM) treated with insulin in comparison to those treated with metformin.
Material and methods: Thirty-one patients with GDM not controlled by diet, included in MeDiGes study (‘Efficacy of metformin in gestational diabetes not controlled by diet in comparison to insulin’), were aleatorized to receive insulin (n=14) or metformin (n=17). Stool samples were collected before the begining of the treatment and in prepartum visit. Clinical-analytical characteristics at baseline and changes in gut microbiota after treatment were compared between both treatment groups.
Results: Clinical-analytical characteristics at baseline are showed in Table 1. Non statistically significant differences were found between both treatment groups in any of parameters. Regarding gut microbiota diversity, after treatment, we found a significantly lower Shannon index in those patients treated with metformin in comparison to those treated with insulin (P=0.04). In metformin group, Firmicutes descended significantly while Proteobacteria increased significantly. No significant changes were found in Bacteroides, Verrucomicrobia, but Actinobacteria tended to reduction (despite non statistical significance). No significant changes were found in insulin group.
| Insulin | Metformin | P value | |
| Age (years) | 33.7±5.6 | 36.6±2.7 | 0.081 |
| Family history of DM (%) | 73.3 | 64.7 | 0.599 |
| Personal history of GDM (%) | 20 | 17.6 | 0.865 |
| Gestational age (weeks) | 29 (16–32) | 30 (23.5–32) | 0.737 |
| Pre-gestational BMI (kg/m2) | 28.6±3.8 | 28.9±6.5 | 0.907 |
| Baseline BMI (kg/m2) | 32.2±4.5 | 32.1±7.2 | 0.978 |
| Fasting glucose (mg/dl) | 85.1±10.6 | 83.5±11.2 | 0.646 |
| HbA1c (%) | 5.2±0.3 | 5.2±0.5 | 0.834 |
Conclusions: • Metformin reduces gut microbiota diversity.
• Metformin cause specific changes in gut microbiota, reducing Firmicutes and increasing Proteobacteria.
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more